Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioventus Inc.
Headquarters: Durham, NC, United States of America
Website: http://www.bioventusglobal.com...
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Robert Claypoole, MBA
Number Of Employees: 930
Enterprise Value: $1,029,885,477
PE Ratio: -18.38
Exchange/Ticker 1: NASDAQ:BVS
Exchange/Ticker 2: N/A
Latest Market Cap: $635,767,808
BioCentury | Dec 21, 2023
Management Tracks
Larson leaving LianBio as CFO
Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
BioCentury | Mar 1, 2022
Management Tracks
Jones leaving BMS to become CMO of Cullinan
Plus Singleton to join Bioventus as CFO, and updates from Noema, Lycia, Avidity and more
BioCentury | Dec 22, 2021
Management Tracks
BIO’s McMurry-Heath joining Bioventus board
Plus: OSE, Centogene and OncoHealth
BioCentury | Nov 2, 2021
Management Tracks
Zaks, Gujrathi join OrbiMed
Plus: BioTheryX, BioCryst, Redx, Tango, Epizyme and more
BioCentury | Mar 6, 2021
Management Tracks
Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition
BioCentury | Feb 12, 2021
Deals
Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta
Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for Versant-grown
BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
Items per page:
1 - 10 of 15